Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer

European Urology, Supplements

Volumn 7, Issue 10, 2008, Pages 618-626

  Colombel, Marc ^a   Soloway, Mark ^b   Akaza, Hideyuki ^c   Böhle, Andreas ^d   Palou, Joan ^e   Buckley, Roger ^f   Lamm, Donald ^g   Brausi, Maurizio ^h   Witjes, J Alfred ⁱ   Persad, Raj ^j  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d HELIOS AGNES KARLL HOSPITAL   (Germany)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f NORTH YORK GENERAL HOSPITAL   (Canada)

^g UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^h AUSL Modena   (Italy)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

more..

Author keywords

Bladder cancer risk factors; Epidemiology; Grading; Non muscle invasive bladder cancer; Risk stratification; Staging

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BCG VACCINE; PYRIDOXINE; RETINOL; ZINC;

BLADDER CANCER; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CARCINOMA IN SITU; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; HUMAN; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDICAL SPECIALIST; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TRANSITIONAL CELL CARCINOMA; WORLD HEALTH ORGANIZATION;

EID: 51349146877     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.08.002     Document Type: Review

References (52)

1. Murta-Nascimento C., Schmitz-Dräger B.J., Zeegers M.P., et al. Epidemiology of urinary bladder cancer: from tumour development to patient's death. World J Urol 25 (2007) 285-295
2. Ferlay J, Bray F, Pisani P, Parkin DM., GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5, version 2.0. Lyon, France: IARC Press; 2004. http://www-dep.iarc.fr. Accessed June 3, 2008.
3. American Cancer Society. Cancer facts and figures 2006 (2006), American Cancer Society, Atlanta, Georgia
4. McCahy P.J., Harris C.A., and Neal E. The accuracy of recording of occupational history in patients with bladder cancer. Br J Urol 79 (1997) 91-93
5. Zeegers M.P., Tan F.E., Dorant E., and van Den Brandt P.A. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89 (2000) 630-639
6. Kirkali Z., Chan T., Manoharan M., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66 (2005) 4-34
7. Silverman D.T., Devesa S.S., Moore L.E., et al. Bladder cancer. In: Schottenfeld D., and Fraumeni J. (Eds). Cancer epidemiology and prevention. 3rd ed. (2006), Oxford University Press, New York, New York
8. Brennan P., Bogillot O., Cordier S., et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 86 (2000) 289-294
9. Vineis P., and Simonato L. Proportion of lung and bladder cancers in males resulting from occupation: a systematic approach. Arch Environ Health 46 (1991) 6-15
10. Kogevinas M., 't Mannetje A., Cordier S., et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control 14 (2003) 907-914
11. International Agency for Research on Cancer. Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42 [suppl 7]. Lyon, France: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; 1987. p. 1-42.
12. Schulte P.A., Ringen K., Hemstreet G.P., and Ward E. Occupational cancer of the urinary tract. Occup Med (Lond) 2 (1987) 85-107
13. Popp W., Schmieding W., Speck M., Vahrenholz C., and Norpoth K. Incidence of bladder cancer in a cohort of workers exposed to 4-chloro-o-toluidine while synthesizing chlordimeform. Br J Ind Med 49 (1992) 529-531
14. Boffetta P., Jourenkova N., and Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 8 (1997) 444-472
15. Golka K., Wiese A., Assennato G., and Bolt H.M. Occupational exposure and urological cancer. World J Urol 21 (2004) 382-391
16. Kantor A.F., Hartge P., Hoover R.N., Narayana A.S., Sullivan J.W., and Fraumeni Jr. J.F. Urinary tract infection and risk of bladder cancer. Am J Epidemiol 119 (1984) 510-515
17. Travis L.B., Curtis R.E., Glimelius B., et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 87 (1995) 524-530
18. Kaldor J.M., Day N.E., Kittelmann B., et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study. Int J Cancer 63 (1995) 1-6
19. Boorjian S., Cowan J.E., Konety B.R., et al., Cancer of the Prostate Strategic Urologic Research Endeavor Investigators. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 177 (2007) 883-887
20. Steinmaus C.M., Nuñez S., and Smith A.H. Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 151 (2000) 693-702
21. Lamm D.L., and Riggs D.R. The potential application of Allium sativum (garlic) for the treatment of bladder cancer. Urol Clin North Am 27 (2000) 157-162
22. Kamat A.M., and Lamm D.L. Chemoprevention of bladder cancer. Urol Clin North Am 29 (2002) 157-168
23. Lamm D.L., Riggs D.R., Shriver J.S., vanGilder P.F., Rach J.F., and DeHaven J.L. Mega-dose vitamins in bladder cancer: a double-blind clinical trial. J Urol 151 (1994) 21-26
24. Sala M., Cordier S., Chang-Claude J., et al. Coffee consumption and bladder cancer in non-smokers: a pooled analysis of case control studies in European countries. Cancer Causes Control 11 (2000) 925-931
25. International Agency for Research on Cancer. Some chemicals that cause tumours of the kidney or urinary bladder in rodents and some other substances. Lyon, France: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; 1999, Volume 73.
26. Goldgar D.E., Easton D.F., Cannon-Albright L.A., and Skolnick M.H. Systematic population-based assessment of cancer risk in first degree relatives of cancer probands. J Natl Cancer Inst 86 (1994) 1600-1608
27. Aben K.K.H., Witjes J.A., Schoenberg M.P., Hulsbergen-van de Kaa C., Verbeek A.L., and Kiemeney L.A. Familial aggregation of urothelial cell carcinoma. Int J Cancer 98 (2002) 274-278
28. Aben K.K.H., Baglietto L., Baffoe A., et al. Segregation analysis of urothelial cell carcinoma. Eur J Cancer 42 (2006) 1428-1433
29. Fleshner N.E., Herr H.W., Stewart A.K., Murphy G.P., Mettlin C., and Menck H.R. The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 78 (1996) 1505-1513
30. Kantor A.F., Hartge P., Hoover R.N., and Fraumeni Jr. J.F. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res 48 (1988) 3853-3855
31. Lynch C.F., and Cohen M.B. Urinary system. Cancer 75 (1995) 316-329
32. El-Bolkainy M.N., Mokhtar N.M., Ghoneim M.A., and Hussein M.H. The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer 48 (1981) 2643-2648
33. Mostafa M.H., Sheweita S.A., and O'Connor P.J. Relationship between schistosomiasis and bladder cancer. Clin Microbiol 1 (1999) 97-111
34. American Urological Association. Guidelines for the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. Linthicum, MD: AUA; 2007. http://www.auanet.org/guidelines/bladcan07.cfm.
35. Hall M.C., Chang S.S., Dalbagni G., et al. Guidelines for the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178 (2007) 2314-2330
36. Kamat A.M., Gee J.R., Dinney C.P., et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175 (2006) 881-885
37. Gaya J.M., Palou J., Algaba F., et al. Management of micropapillary carcinoma of the bladder-the case for conservative management of patients with non-muscle invasive and without CIS [abstract 155]. Eur Urol Suppl 6 (2007) 61
38. In: Sobin D.H., and Wittekind C.H. (Eds). TNM classification of malignant tumours. 6th ed (2002), Wiley-Liss, New York, New York 199-202
39. Epstein J.I., Amin M.B., Reuter V.R., and Mostofi F.K. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 22 (1998) 1435-1448
40. Sauter G., Algaba F., Amin M., et al. Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble J.N., Sauter G., Epstein Jl, and Sesterhenn I. (Eds). WHO classification of tumours of the urinary system and male genital organs (2004), IARC Press, Lyon, France
41. MacLennan G.T., Kirkali Z., and Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 51 (2007) 889-898
42. Lopez-Beltran A., and Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 46 (2004) 170-176
43. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou J. European Association of Urology guidelines on TaT1 (Non-muscle invasive) bladder cancer. Update March 2008. Arnhem, the Netherlands: EAU; 2008. http://www.uroweb.org/fileadmin/tx_eauguidelines/TaT1%20Bladder%20Cancer.pdf.
44. Murphy W.M., Takezawa K., and Maruniak N.A. Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J Urol 168 (2002) 968-972
45. Yorukoglu K., Tuna B., Dikicioglu E., et al. Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. Virchows Arch 443 (2003) 734-740
46. Gonul I.I., Poyraz A., Unsal C., Acar C., and Alkibay T. Comparison of 1998 WHO/ISUP and 1973 WHO classifications for interobserver variability in grading of papillary urothelial neoplasms of the bladder. Pathological evaluation of 258 cases. Urol Int 78 (2007) 338-344
47. World Health Organization. World cancer report, 2003 (2003), IARC Press, Lyon, France p. 229
48. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
49. European Organisation for Research and Treatment of Cancer. EORTC risk tables for predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer. http://www.eortc.be/tools/bladdercalculator/default.htm.
50. Böhle A. Management of superficial bladder cancer: risk calculators-simple office-based risk calculator. http://www.bladder-cancer-course.org/sites/03_06_01_02.html.
51. Mian C., and Pycha A. Risk stratification in superficial bladder cancer: fact or fiction. EAU-EBU Update Series 5 (2007) 63-69
52. Sylvester RJ. Reply to Dr Maffezzini's letter to the editor re: Richard J. Sylvester, Adrian P.M. van der Meijden, Willem Oosterlinck, J. Alfred Witjes, Christian Bouffioux, Louis Denis and Donald W.W. Newling. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77. Eur Urol 2006;50:624-5.